Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Serotonin Transporter Density in Late-life Depression With and Without Dementia

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01548937
First received: December 29, 2011
Last updated: March 6, 2012
Last verified: October 2011

December 29, 2011
March 6, 2012
May 2010
October 2012   (final data collection date for primary outcome measure)
Evaluate the differences of serotonin transporter activity among depressive patient with or without dementia. [ Time Frame: three years ] [ Designated as safety issue: Yes ]
To expand the database of I-123 ADAM SPECT imaging in AD depressive and cognitively depressive patients to refine the definition of a positive scan in patient with AD and MDD.
Same as current
Complete list of historical versions of study NCT01548937 on ClinicalTrials.gov Archive Site
Evaluate the relationship between the serotonin transporter activity and F-18 FDG PET image patter. [ Time Frame: three years ] [ Designated as safety issue: Yes ]
To expand the safety database of I-123 ADAM SPECT imaging Safety variables include adverse event count, lab parameters, vital signs, and ECG. Comparison will be generally made to baseline, as appropriate.
Same as current
Not Provided
Not Provided
 
Serotonin Transporter Density in Late-life Depression With and Without Dementia
Serotonin Transporter Density in Late-life Depression With and Without Dementia

This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive); each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

This study is expected to be completed in a period of 3 years.

Depression and dementia are the two common psychiatric disorders in the elder subjects. Alzheimer's disease (AD) is the most frequent cause of dementia and about 20% of them have depression. Depression subjects are associated with more rapid cognitive decline, a poorer response to treatment. Post mortem study showed close relationship between AD and disruptions of the serotonergic system, including loss of serotnergic neurons at brain stem. However, the alternations in presynaptic serotonin function relative to demented or non-demented subjects remain to be investigated in living subjects. In this study, the investigators will collect 40 elder subjects (i.e., age above or equal to 50 years old). The serotonin transporter activity will be compared between subjects with or without dementia using I-123 ADAM images. The single photon emission tomography (SPECT) will be compared to recent (within 6 months) F-18 FDG PET images for further investigation.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Melancholia
Drug: I-123 ADAM

This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

Other Name: I-123 ADAM
Experimental: I-123 ADAM
I-123 ADAM Serotonin transporter imaging
Intervention: Drug: I-123 ADAM
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
40
December 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients may be enrolled in the AD depressive group if they:

    • Are males or females at least 50 years of age;
    • Fulfilled the DSM-IV criteria for Major depressive disorder (APA, 1994) by MINI interview.
    • Meet the NINCDS/ADRDA(National institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association) criteria for probable AD
    • A Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive;
    • Give informed consent. If the patient is incapable of giving informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm assent).
  2. Patients may be enrolled in the cognitively depressive group if they:

    • Are males or females at least 50 years of age;
    • Fulfilled the DSM-IV criteria for Major depressive disorder (APA, 1994) by MINI interview.
    • Memory function above the lower normal limits (i.e. 1.5 SD above the mean) on tests for episodic memory.
    • Clinical Dementia Rating = 0. Memory Box score must be 0.
    • Cognitively normal, based on an absence of significant impairment in cognitive functions or ADL.
    • A MMSE score at screening > 24 for those with education level of 6 years or above and > 17 for those are illiterate;
    • Give informed consent.

Exclusion Criteria:

  • Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
  • Conditions affecting brain structure or function (e.g., stroke, diabetes, head trauma, depression) or use of cognitively
  • Substance abuse.
  • Alcohol dependence
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01548937
98-2132A
Yes
Chang Gung Memorial Hospital
Chang Gung Memorial Hospital
Not Provided
Not Provided
Chang Gung Memorial Hospital
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP